RTW Investments LP Acquires 47,447 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

RTW Investments LP lifted its position in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 1.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,834,794 shares of the company's stock after acquiring an additional 47,447 shares during the period. RTW Investments LP owned about 16.35% of UroGen Pharma worth $40,841,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in URGN. Acorn Capital Advisors LLC acquired a new position in UroGen Pharma during the fourth quarter valued at $16,149,000. Nantahala Capital Management LLC acquired a new stake in UroGen Pharma in the fourth quarter valued at approximately $14,608,000. Silverarc Capital Management LLC lifted its stake in UroGen Pharma by 24.3% in the fourth quarter. Silverarc Capital Management LLC now owns 1,120,473 shares of the company's stock valued at $11,933,000 after acquiring an additional 219,344 shares during the last quarter. Rosalind Advisors Inc. bought a new stake in shares of UroGen Pharma during the 4th quarter worth about $9,266,000. Finally, DAFNA Capital Management LLC increased its holdings in shares of UroGen Pharma by 7.3% during the 4th quarter. DAFNA Capital Management LLC now owns 492,515 shares of the company's stock valued at $5,245,000 after acquiring an additional 33,600 shares during the last quarter. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

UroGen Pharma Stock Performance

Shares of URGN traded up $0.66 during trading hours on Monday, reaching $7.97. 3,417,687 shares of the company traded hands, compared to its average volume of 598,127. UroGen Pharma Ltd. has a 1-year low of $6.46 and a 1-year high of $20.70. The stock has a market cap of $367.47 million, a P/E ratio of -2.53 and a beta of 0.66. The stock's fifty day moving average is $10.59 and its 200 day moving average is $10.88. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). The business had revenue of $20.25 million during the quarter, compared to the consensus estimate of $22.71 million. Equities research analysts anticipate that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

URGN has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $55.00 target price on shares of UroGen Pharma in a research report on Tuesday, May 13th. Scotiabank began coverage on shares of UroGen Pharma in a report on Wednesday, April 16th. They issued a "sector outperform" rating and a $23.00 target price on the stock. D. Boral Capital restated a "buy" rating and set a $25.00 price target on shares of UroGen Pharma in a report on Thursday, May 8th. LADENBURG THALM/SH SH initiated coverage on UroGen Pharma in a research note on Wednesday, February 19th. They set a "buy" rating and a $31.00 target price for the company. Finally, Guggenheim reaffirmed a "buy" rating on shares of UroGen Pharma in a report on Tuesday, April 29th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $32.86.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.